From the Press
KSM Research & Innovation And Genetika+ Partner To Seek AI Solutions For Personalization Of Depression Treatment
Kahn-Sagol-Maccabi (KSM) and Genetika+ form a research partnership to develop and validate AI that personalizes and speeds up an optimal depression treatment
Genetika+ Publication Featured in Future Medicine
Find out more about the extraordinary work happening at Genetika+ as we bring precision medicine into practice to optimize depression treatment
Genetika+ awarded up to €17.5M from European Commission's European Innovation Council (EIC) Accelerator for Europe’s high potential start-ups
Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
Dr. Daphna Laifenfeld Speaks at PMWC 2022
Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Genetika+ Wins the BioNJ BioPartnering Company & Pitch Presentation MedTech Award at the BioNJ 12th Annual Bio Partnering Conference
Co-Sponsored by J.P. Morgan and Johnson & Johnson, Genetika+ Gives Award Winning Presentation
Female Led Genetika+ Grew and Gained Funding Through MassChallenge
How did a female-led startup from the MC18 Israel cohort turn their MassChallenge experience into a $10 million Series A funding round? Learn more about Genetika+ and its co-founders, Talia Cohen Solal and Daphna Laifenfeld, in our most recent case study.
Genetika+ CEO Talia Cohen Solal Brings Precision Medicine to Brain Health
Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time.
Genetika+, Pioneer in Personalized Medicine for Psychiatry, Raises $10 Million in an Oversubscribed Series A
Proceeds to fund clinical trials and scale up in the U.S. market. New investment underscores the company’s promise to transform precision medicine and mental health.
A successful female entrepreneur, Talia Cohen Solal is an extremely driven, compassionate, and curious individual. As the CEO & Co-Founder of Genetika+, a biotech start-up specialized in developing new tools for personalized medicine in major depression, she is advancing treatment in a much-needed space. In this interview, she speaks on a range of topics – from a unique scientific approach to depression treatment, to her journey from academic to entrepreneur, from challenges faced in the industry, to her passion for entrepreneurship. Here are some excerpts from the interview.
Discover 5 Top Healthcare Startups tackling Depression
Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the healthcare sector. This time, you get to discover 5 hand-picked startups tackling depression and mental health.
Israeli biotech company Matricelf wins Calcalist’s StartUp+ competition
The company developed a platform for 3D printing of tissues and organs. Genetika+, which developed a personalized technology for digital health took second place; winners awarded monetary prizes and office space.